ADMA Biologics Affirms FY2026 Sales Guidance of $530.000M-$560.000M vs $559.495M Est

Benzinga Newsdesk www.benzinga.com Negative 68.3%

Neg 68.3% Neu 0% Pos 0%

ADMA Biologics (NASDAQ:ADMA) affirms FY2026 sales outlook from $530.000 million-$560.000 million to $530.000 million-$560.000 million vs $559.495 million estimate.